Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06347861 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT06347861 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 52 participants.
The verdict
NCT06347861, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of the study is to look at how various tablets of a study medicine called vepdegestrant are processed in the body. This will be studied in healthy adult participants after food. This study looks at how the medicine is changed and removed from the body after a participant takes it. This study is seeking for participant who: * are healthy males, and healthy females who do not have the possibility to have children. * are 18 years of age or older. * weigh more than 45 Kilograms (99 pounds). The study consists of 3 treatments. Each participant will be assigned by chance to receive the 3 treatments in a certain sequence. This will be done over 3 study periods. Each treatment consists of a single amount of vepdegestrant taken by mouth in each study period. There will be a washout period between each study periods. The washout period is the time allowed for the medicine to get washed out from the body. How the medicine was processed will be calculated following each dose in each period. The total study duration is about 13 weeks.
Interventions
- DRUG single dose of vepdegestrant as tablet formulation (Treatment A)
- DRUG single dose of vepdegestrant as tablet formulation (Treatment B)
- DRUG single dose of vepdegestrant as tablet formulation (Treatment C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2024-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06347861
The ClinicalTrials.gov registry entry for NCT06347861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which single dose of vepdegestrant as tablet formulation (Treatment A) is the first listed.
NCT06347861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06347861 about?
NCT06347861 is a clinical study titled "A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy Adults". The purpose of the study is to look at how various tablets of a study medicine called vepdegestrant are processed in the body. This will be studied in healthy adult participants after food. This study looks at how the medicine is changed and removed from the body after a participant takes it. This...
What is the current status of trial NCT06347861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2024-04-02. Estimated completion is 2024-08-08.
What interventions are being tested in trial NCT06347861?
The interventions under investigation include: single dose of vepdegestrant as tablet formulation (Treatment A) (DRUG), single dose of vepdegestrant as tablet formulation (Treatment B) (DRUG), single dose of vepdegestrant as tablet formulation (Treatment C) (DRUG).
Who is sponsoring clinical trial NCT06347861?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.